Elanco (ELAN) Animal Health announced that Zenrelia has received approval by the European Commission. This approval by the EU reinforces Zenrelia’s status as a highly effective, convenient, and safe once-daily oral JAK inhibitor. Zenrelia’s approval represents a significant milestone in the EU canine dermatology market, offering a once-daily tablet solution for control pruritus associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco price target raised to $18 from $17 at UBS
- Starbucks downgraded, Oracle initiated: Wall Street’s top analyst calls
- Leerink upgrades Elanco following channel checks, semiannual veterinarian survey
- Elanco upgraded to Outperform from Market Perform at Leerink
- Elanco receives USDA approval for TruCan Ultra CIV H3N2/H3N8